ovarian hyperstimulation syndrome
Conditions
Interventions
Control group:On the basis of lifestyle intervention bromocriptine is applied (starting from the oocyte retrieval day 2.5 mg/day rectally administered continuous medication for 6 days).
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Translation of Study Inclusion Criteria and Related Definitions Subjects were included if they: Visited the Reproductive Center of Peking University Third Hospital due to "infertility" for in vitro fertilization (IVF)-assisted reproduction treatment; Underwent controlled ovarian hyperstimulation (COH); Were identified as having a high risk of ovarian hyperstimulation syndrome (OHSS) on the oocyte retrieval day; Had fresh cycle embryo transfer canceled for OHSS prevention. Diagnostic Criteria for Infertility Infertility is a state of subfertility, defined as the failure of a couple to achieve a clinical pregnancy after at least 12 months of regular, unprotected sexual intercourse. Clinical pregnancy refers to the presence of clinical signs of pregnancy, with confirmation by ultrasound of one or more gestational sacs. Population at High Risk of OHSS Referencing the definition used by the Reproductive Center of our hospital, individuals meeting one or more of the following criteria are classified as being at high risk of OHSS: Serum estradiol (E2) level = 15,000 pmol/L on the trigger day; Number of retrieved oocytes = 20; Serum estradiol (E2) level = 10,000 pmol/L and number of retrieved oocytes = 15 on the trigger day. Inclusion Criteria Subjects must meet all the following criteria to be included in the study: (1)Age = 35 years; (2)Body mass index (BMI) 3500 pg/mL or number of retrieved oocytes > 15 on the trigger day; (4)Fresh cycle embryo transfer canceled.
Exclusion criteria
Exclusion criteria: (1) Those who do not accept or cannot tolerate traditional Chinese medicine treatment; (2) Those who use drugs that may have a preventive effect on OHSS such as metformin; (3) Those lacking necessary prognostic information; (4) Those who have not signed the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of moderate to severe ovarian hyperstimulation syndrome (OHSS).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vascular Endothelial Growth Factor (VEGF);OHSS Clinical Symptom Self-Assessment Scale;Signs;Serum Estradiol;Visual Analogue Scale (VAS) Score; | — |
Countries
China
Contacts
Public ContactXinXiyan
Peking University Third Hospital
Outcome results
None listed